Log In
Print
BCIQ
Print
Print this Print this
 

VY-SOD101

  Manage Alerts
Collapse Summary General Information
Company Voyager Therapeutics Inc.
DescriptionAAV-based gene therapy designed to knock down mutant superoxide dismutase 1 (SOD1)
Molecular Target Superoxide dismutase 1 (SOD1)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPreclinical
Standard IndicationAmyotrophic lateral sclerosis (ALS)
Indication DetailsTreat monogenic amyotrophic lateral sclerosis (ALS)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today